Scarica l'app Stockscreener
18.61
1.06%
-0.20
Dopo l'orario di chiusura:
18.61
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché TNDM Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$18.81
Aprire:
$18.25
Volume 24 ore:
1.03M
Relative Volume:
0.54
Capitalizzazione di mercato:
$1.27B
Reddito:
$1.01B
Utile/perdita netta:
$-204.71M
Rapporto P/E:
-6.0637
EPS:
-3.0691
Flusso di cassa netto:
$-29.67M
1 W Prestazione:
-20.20%
1M Prestazione:
-26.24%
6M Prestazione:
+41.95%
1 anno Prestazione:
-1.48%
Intervallo 1D:
$18.08
$19.09
Intervallo di 1 settimana:
$18.08
$22.97
Portata 52W:
$9.98
$29.65
Tandem Diabetes Care Inc Stock (TNDM) Company Profile
Nome
Tandem Diabetes Care Inc
Settore
Industria
Telefono
858-366-6900
Indirizzo
12400 HIGH BLUFF DRIVE, San Diego, CA
Compare TNDM vs ABT, SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TNDM
Tandem Diabetes Care Inc
|
18.61 | 1.27B | 1.01B | -204.71M | -29.67M | -3.0691 |
ABT
Abbott Laboratories
|
102.87 | 178.75B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
331.54 | 126.97B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
86.63 | 111.22B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
62.82 | 93.36B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
81.05 | 46.73B | 6.07B | 1.06B | 1.34B | 1.8063 |
Tandem Diabetes Care Inc Stock (TNDM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-19 | Aggiornamento | Truist | Hold → Buy |
| 2026-03-17 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2026-02-23 | Aggiornamento | Lake Street | Hold → Buy |
| 2026-02-20 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2026-01-27 | Ripresa | TD Cowen | Buy |
| 2025-12-16 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2025-10-21 | Ripresa | Stifel | Hold |
| 2025-09-08 | Iniziato | Oppenheimer | Outperform |
| 2025-08-12 | Aggiornamento | Citigroup | Sell → Neutral |
| 2025-08-07 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2025-07-09 | Downgrade | Citigroup | Neutral → Sell |
| 2025-06-16 | Iniziato | Truist | Hold |
| 2025-04-10 | Iniziato | Mizuho | Neutral |
| 2025-03-05 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-03-04 | Downgrade | Citigroup | Buy → Neutral |
| 2025-03-03 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-02-28 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2024-12-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-11-06 | Iniziato | Bernstein | Outperform |
| 2024-10-04 | Iniziato | Goldman | Neutral |
| 2024-10-02 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-08-22 | Iniziato | Morgan Stanley | Equal-Weight |
| 2024-08-08 | Iniziato | Canaccord Genuity | Buy |
| 2024-05-30 | Iniziato | Redburn Atlantic | Buy |
| 2024-05-22 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-04-29 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-04-25 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-03-26 | Aggiornamento | Stifel | Hold → Buy |
| 2023-08-04 | Downgrade | Citigroup | Buy → Neutral |
| 2023-05-05 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-04-24 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2023-03-29 | Iniziato | UBS | Neutral |
| 2023-01-26 | Iniziato | Wolfe Research | Peer Perform |
| 2022-11-15 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2022-10-18 | Iniziato | Barclays | Overweight |
| 2022-10-12 | Iniziato | Jefferies | Buy |
| 2022-08-09 | Downgrade | Wells Fargo | Overweight → Underweight |
| 2022-03-02 | Ripresa | BofA Securities | Neutral |
| 2022-01-19 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2021-07-21 | Ripresa | Cowen | Outperform |
| 2021-05-25 | Iniziato | Barclays | Underweight |
| 2020-12-15 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-08-20 | Iniziato | Wells Fargo | Overweight |
| 2020-07-31 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-07-06 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-06-18 | Reiterato | Raymond James | Outperform |
| 2020-04-24 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2020-03-23 | Downgrade | Guggenheim | Buy → Neutral |
| 2020-03-05 | Iniziato | Citigroup | Neutral |
| 2020-02-06 | Iniziato | Raymond James | Outperform |
| 2020-02-04 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2019-10-18 | Iniziato | Guggenheim | Buy |
| 2019-10-04 | Aggiornamento | UBS | Neutral → Buy |
| 2019-05-17 | Reiterato | BofA/Merrill | Neutral |
| 2019-05-13 | Iniziato | SVB Leerink | Outperform |
| 2019-03-08 | Iniziato | BMO Capital Markets | Outperform |
| 2019-03-05 | Reiterato | BofA/Merrill | Neutral |
| 2019-02-27 | Reiterato | Lake Street | Buy |
| 2018-11-21 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2018-09-26 | Reiterato | Dougherty & Company | Buy |
| 2018-09-26 | Reiterato | Piper Jaffray | Overweight |
Mostra tutto
Tandem Diabetes Care Inc Borsa (TNDM) Ultime notizie
Market Outlook: Will Tandem Diabetes Care Inc benefit from AI trends2026 Sector Moves & Technical Buy Zone Confirmation - baoquankhu1.vn
Assessing Tandem Diabetes Care (TNDM) Valuation After Recent Share Price Weakness - Yahoo Finance
Tandem Diabetes adds Android support for Mobi insulin pump - Investing.com
Tandem Diabetes Care, Inc. (TNDM) Stock forecasts - Yahoo Finance UK
JPMorgan Chase Reduces Stake in Tandem Diabetes Care - National Today
JPMorgan Chase & Co. Sells 203,183 Shares of Tandem Diabetes Care, Inc. $TNDM - MarketBeat
Tandem Diabetes Care to Announce Q1 2026 Results on May 7 - National Today
Tandem Diabetes Care to Announce First Quarter 2026 Financial Results on May 7, 2026 - Yahoo Finance
Diabetes Focused MiniMed Recovery Story Builds As Pipeline Improves - Sahm
Tandem Diabetes Care, Inc. (TNDM) Stock Forecasts - Yahoo Finance
Tandem Diabetes Care (TNDM) reports Q4 earnings: What key metrics have to say - MSN
Earnings Report: Should value investors consider Tandem Diabetes Care Inc2026 Top Decliners & Fast Momentum Entry Tips - baoquankhu1.vn
Tandem Diabetes Care Stock Hits Day Low Amid Price Pressure at $20.93 - Markets Mojo
Stock List: Research Stocks from Around the World - gurufocus.com
Tandem Diabetes and Roche Reach a Patent Settlement - MSN
Board asks shareholders to approve 3.26M-share increase; TNDM files proxy (TNDM) - Stock Titan
Tandem Diabetes Care (NASDAQ:TNDM) Trading Down 6.6%Time to Sell? - MarketBeat
Elanco, Tandem Diabetes, Fortrea, Natera, and Myriad Genetics Shares Plummet, What You Need To Know - TradingView
[SCHEDULE 13G/A] TANDEM DIABETES CARE INC Amended Passive Investment Disclosure - Stock Titan
Tandem Diabetes Care, Inc. Investigated by the Portnoy Law Firm - GlobeNewswire
Mizuho maintains Tandem Diabetes Care (TNDM) neutral recommendation - MSN
Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Assenagon Asset Management S.A. Invests $26.99 Million in Tandem Diabetes Care, Inc. $TNDM - MarketBeat
Strength seen in Tandem Diabetes Care (TNDM): Can its 9.1% jump turn into more strength? - msn.com
Tandem Diabetes Care, Inc. (TNDM) reports Q4 loss, tops revenue estimates - MSN
Tandem Diabetes Care Maps Pharmacy Shift, Targets 65% Gross Margin and 2026 Mobi Tubeless Launch - marketbeat.com
Here’s why the Brown Capital Management Small Company Fund sold Tandem Diabetes Care (TNDM) - MSN
Reasons to hold Tandem Diabetes stock in your portfolio for now - MSN
US875372AE4 Latest News and Headlines - TradingView
US875372AE4 Bond Analysis — Key Metrics - TradingView
Tandem upgraded at Truist on pharmacy model (TNDM:NASDAQ) - Seeking Alpha
US875372AE4 Bond Price and Chart — FWB:US875372AE4 - TradingView
Tandem Diabetes Care (NASDAQ:TNDM) Stock Price Up 5.3% on Analyst Upgrade - MarketBeat
Nvidia To $323? Here Are 10 Top Analyst Forecasts For Thursday - Benzinga
This Union Pacific Analyst Turns Bullish; Here Are Top 3 Upgrades For Wednesday - Benzinga
Truist Financial Upgrades Tandem Diabetes Care (NASDAQ:TNDM) to "Buy" - MarketBeat
Tandem Diabetes Care analysts boost their forecasts after upbeat Q4 results - MSN
Tandem Diabetes (TNDM) Receives Upgrade Amid Revenue Growth Pros - GuruFocus
Tandem Diabetes (TNDM) EVP exercises 7,414 RSUs and sells 187 shares - Stock Titan
Lake Street upgrades Tandem Diabetes Care (TNDM) - MSN
Strength Seen in Tandem Diabetes Care (TNDM): Can Its 9.1% Jump Turn into More Strength? - Yahoo Finance
Piper Sandler upgrades Tandem Diabetes Care (TNDM) - MSN
Tandem Diabetes (TNDM) Stock Upgraded by Piper Sandler Amid Stra - GuruFocus
Piper Sandler Upgrades Tandem Diabetes Care (TNDM) to Overweight - GuruFocus
Tandem Diabetes Care (TNDM) insider files resale notice; 2 shares sold at $45.62 - Stock Titan
Tandem Diabetes Care Stock Upgrade & Market Outlook 2026News and Statistics - IndexBox
Why Are Tandem Diabetes (TNDM) Shares Soaring Today - Yahoo Finance
Bullish Call On Tandem Diabetes Signals Long-Term Growth Confidence - Benzinga
Tandem Diabetes Care Inc Azioni (TNDM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Tandem Diabetes Care Inc Azioni (TNDM) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Novara Mark David | EVP & CHIEF COMMERCIAL OFFICER |
Mar 17 '26 |
Sale |
23.05 |
187 |
4,310 |
37,656 |
0.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):